Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pinitol (3-O-methyl-D-chiro-inositol) is a naturally occurring cyclic sugar alcohol and a methyl ether of D-chiro-inositol, primarily found in soy and various legumes. It functions as an insulin sensitizer and has been investigated for the treatment of type 2 diabetes and metabolic syndrome to improve glycemic control and insulin resistance. In the field of neurodegeneration, Humanetics Pharmaceuticals is developing a proprietary formulation of pinitol, designated NIC5-15, for Alzheimer's disease. NIC5-15 is reported to act as a Notch-sparing γ-secretase modulator, which reduces the production of amyloid-beta (Aβ) peptides while preserving the cleavage of other γ-secretase substrates like Notch. The compound has reached Phase 2 clinical trials for Alzheimer's disease and is also commercially available as a dietary supplement.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pinitol.